An international research team revealed the atomic‐level structure of the human peptidase enzyme meprin β (beta).
Researchers have discovered that amyloid peptides are harmful to the blood vessels that supply the brain with blood in Alzheimer's disease, thus accelerating cognitive decline by limiting oxygen-rich blood and nutrients.
A new study identifies a potential treatment window of several years for plaques in the brain considered to cause memory loss in diseases such as Alzheimer's.
Researchers used a specific molecule in green tea extract, EGCG, to control metal associated amyloid beta aggregates associated with Alzheimer's disease and other neurodegenerative disorders.
Researchers have identified biomarkers for Alzheimer's disease which accurately predict the development of the disease years prior to symptoms developing.
A new study has pinpointed a catalytic trigger for the onset of Alzheimer's disease. The findings could play a central role in the diagnostics and new drug development for neurodegenerative diseases.
Bexarotene, an anti-cancer drug which is about to be tested in a clinical trial as a potential treatment for Alzheimer's disease, fails to reduce amyloid plagues; according to researchers replicating the original study.
Researchers have successfully measured a significant difference between the brains of patients with an inherited form of Alzheimer's disease and their healthy family members who do not carry the genetic mutation for the disease.
Researchers discover early accumulation of amyloid plaques in the temporal lobe is associated with cognitive decline. The finding could serve as a new biomarker for the early detection of Alzheimer's disease.
Researchers reveal how two classes of drug compounds, which are currently in trial, work to fight Alzheimer's disease. They also identify possible causes of early onset hereditary forms of AD.